Illumina, Inc. (ILMN)
ILMN Stock Price Chart
Explore Illumina, Inc. interactive price chart. Choose custom timeframes to analyze ILMN price movements and trends.
ILMN Company Profile
Discover essential business fundamentals and corporate details for Illumina, Inc. (ILMN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
28 Jul 2000
Employees
8.97k
Website
https://www.illumina.comCEO
Jacob Thaysen
Description
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
ILMN Financial Timeline
Browse a chronological timeline of Illumina, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is $1.24, while revenue estimate is $1.13bn.
Earnings released on 30 Apr 2026
EPS came in at $1.15 surpassing the estimated $1.05 by +9.52%, while revenue for the quarter reached $1.09bn , beating expectations by +1.66%.
Earnings released on 5 Feb 2026
EPS came in at $1.35 surpassing the estimated $1.24 by +8.87%, while revenue for the quarter reached $1.16bn , beating expectations by +3.60%.
Earnings released on 30 Oct 2025
EPS came in at $1.34 surpassing the estimated $1.17 by +14.53%, while revenue for the quarter reached $1.08bn , beating expectations by +1.65%.
Earnings released on 31 Jul 2025
EPS came in at $1.19 surpassing the estimated $1.02 by +16.67%, while revenue for the quarter reached $1.06bn , missing expectations by -0.56%.
Earnings released on 8 May 2025
EPS came in at $0.97 surpassing the estimated $0.94 by +3.19%, while revenue for the quarter reached $1.04bn , beating expectations by +1.52%.
Earnings released on 6 Feb 2025
EPS came in at $0.86 falling short of the estimated $0.92 by -6.52%, while revenue for the quarter reached $1.10bn , beating expectations by +3.00%.
Earnings released on 4 Nov 2024
EPS came in at $1.14 surpassing the estimated $0.88 by +29.69%, while revenue for the quarter reached $1.08bn , beating expectations by 0.00%.
Earnings released on 6 Aug 2024
EPS came in at $0.36 surpassing the estimated $0.11 by +228.47%, while revenue for the quarter reached $1.11bn , beating expectations by +1.73%.
Earnings released on 2 May 2024
EPS came in at $0.09 surpassing the estimated $0.04 by +106.42%, while revenue for the quarter reached $1.08bn , beating expectations by +2.44%.
Earnings released on 8 Feb 2024
EPS came in at $0.14 surpassing the estimated $0.02 by +686.08%, while revenue for the quarter reached $1.12bn , beating expectations by +3.13%.
Earnings released on 9 Nov 2023
EPS came in at $0.33 surpassing the estimated $0.13 by +153.85%, while revenue for the quarter reached $1.12bn , missing expectations by -1.03%.
Earnings released on 9 Aug 2023
EPS came in at $0.32 surpassing the estimated $0.02 by +1.64k%, while revenue for the quarter reached $1.18bn , beating expectations by +1.08%.
Earnings released on 25 Apr 2023
EPS came in at $0.08 surpassing the estimated $0.03 by +215.83%, while revenue for the quarter reached $1.09bn , missing expectations by -6.82%.
Earnings released on 7 Feb 2023
EPS came in at $0.14 falling short of the estimated $0.19 by -26.32%, while revenue for the quarter reached $1.08bn , beating expectations by +1.04%.
Earnings released on 3 Nov 2022
EPS came in at $0.34 surpassing the estimated $0.29 by +17.24%, while revenue for the quarter reached $1.12bn , beating expectations by +0.36%.
Earnings released on 11 Aug 2022
EPS came in at $0.57 falling short of the estimated $0.63 by -9.52%, while revenue for the quarter reached $1.16bn , missing expectations by -4.90%.
Earnings released on 5 May 2022
EPS came in at $1.07 surpassing the estimated $0.87 by +22.99%, while revenue for the quarter reached $1.22bn , beating expectations by +0.32%.
Earnings released on 10 Feb 2022
EPS came in at $0.75 surpassing the estimated $0.49 by +53.06%, while revenue for the quarter reached $1.20bn , beating expectations by +6.36%.
Earnings released on 4 Nov 2021
EPS came in at $1.45 surpassing the estimated $1.24 by +16.94%, while revenue for the quarter reached $1.11bn , beating expectations by +6.24%.
Earnings released on 5 Aug 2021
EPS came in at $1.87 surpassing the estimated $1.36 by +37.50%, while revenue for the quarter reached $1.13bn , beating expectations by +10.64%.
ILMN Stock Performance
Access detailed ILMN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
